UBAP1 and prostate carcinoma: No UAP mutant was reported in these two higher model animals; however, UAP1 was found to be overexpressed in prostate cancer and protect against inhibitors of N-linked glycosylation, conferring a growth advantage (Itkonen et al., 2015).